BRPI0915942A2 - método para produção de compostos medicinais contendo dabigatrana - Google Patents

método para produção de compostos medicinais contendo dabigatrana

Info

Publication number
BRPI0915942A2
BRPI0915942A2 BRPI0915942-8A BRPI0915942A BRPI0915942A2 BR PI0915942 A2 BRPI0915942 A2 BR PI0915942A2 BR PI0915942 A BRPI0915942 A BR PI0915942A BR PI0915942 A2 BRPI0915942 A2 BR PI0915942A2
Authority
BR
Brazil
Prior art keywords
medicinal compounds
compounds containing
dabigatran
producing medicinal
containing dabigatran
Prior art date
Application number
BRPI0915942-8A
Other languages
English (en)
Inventor
Bernhard Edmund Radtke Guido
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40030321&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0915942(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of BRPI0915942A2 publication Critical patent/BRPI0915942A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

método para produção de compostos medicinais contendo dabigatrana a presente invenção refere-se a um processo aperfeiçoado para preparar uma nova formulação de medicamento de etexilato 5 de dabigatrana de substância ativa de fórmula i na forma de sal de ácido metanossulfônico da mesma, e essa nova formulação de medicamento como tal.
BRPI0915942-8A 2008-07-14 2009-07-13 método para produção de compostos medicinais contendo dabigatrana BRPI0915942A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08160335 2008-07-14
EP08160335.9 2008-07-14
PCT/EP2009/058900 WO2010007016A1 (en) 2008-07-14 2009-07-13 Method for manufacturing medicinal compounds containing dabigatran

Publications (1)

Publication Number Publication Date
BRPI0915942A2 true BRPI0915942A2 (pt) 2019-04-09

Family

ID=40030321

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915942-8A BRPI0915942A2 (pt) 2008-07-14 2009-07-13 método para produção de compostos medicinais contendo dabigatrana

Country Status (16)

Country Link
US (2) US20110123635A1 (pt)
EP (2) EP2296631A1 (pt)
JP (1) JP2011527318A (pt)
KR (1) KR20110039261A (pt)
CN (1) CN102099012A (pt)
AR (1) AR072557A1 (pt)
AU (1) AU2009272796A1 (pt)
BR (1) BRPI0915942A2 (pt)
CA (1) CA2730218A1 (pt)
CL (1) CL2010001588A1 (pt)
IL (1) IL209346A0 (pt)
MX (1) MX2011000480A (pt)
NZ (1) NZ589746A (pt)
RU (1) RU2529798C2 (pt)
TW (1) TWI436994B (pt)
WO (1) WO2010007016A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005061623A1 (de) 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen
US20110129538A1 (en) * 2008-03-28 2011-06-02 Boehringer Ingelheim International Gmbh Process for preparing orally administered dabigatran formulations
AR072143A1 (es) * 2008-06-16 2010-08-11 Boehringer Ingelheim Int Procedimiento para la preparacion de un producto intermedio para la sintesis de etexilato de dabigatran
AU2009315729A1 (en) 2008-11-11 2010-05-20 Boehringer Ingelheim International Gmbh Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
US8399678B2 (en) 2009-11-18 2013-03-19 Boehringer Ingelheim International Gmbh Process for the manufacture of dabigatran etexilate
SI2542224T1 (sl) * 2010-03-01 2014-10-30 Ratiopharm Gmbh Oralni farmacevtski sestavek, ki vsebuje dabigatran eteksilat
PL2588090T3 (pl) 2010-07-01 2017-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Doustne farmaceutyczne postacie dawkowania zawierające eteksylan dabigatranu i jego farmaceutycznie dopuszczalne sole
JP2015500853A (ja) 2011-12-22 2015-01-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 即時放出マルチユニットペレットシステム
HUE056194T2 (hu) * 2012-02-21 2022-01-28 Towa Pharmaceutical Europe S L Dabigatrán-etexilát orális gyógyszerészeti készítményei
WO2014001220A1 (en) 2012-06-25 2014-01-03 Boehringer Ingelheim International Gmbh Method for prevention of stroke
CN103127109B (zh) * 2013-02-05 2014-08-13 南京华威医药科技开发有限公司 含达比加群酯或其盐和水合物的药用组合
CN111012756B (zh) * 2013-06-21 2023-06-13 四川海思科制药有限公司 一种达比加群酯药物组合物及其制备方法
CN105640909B (zh) 2014-11-14 2019-09-20 正大天晴药业集团股份有限公司 一种含有达比加群酯的药用组合物
CN109125274A (zh) * 2017-06-28 2019-01-04 上海美悦生物科技发展有限公司 注射用苯并咪唑类药用酸组合物及其制备方法和用途
CN110339193B (zh) * 2018-04-04 2022-04-29 上海汉都医药科技有限公司 含达比加群酯的药物组合物及其制备方法
CN111840245B (zh) * 2019-04-28 2023-07-18 成都倍特药业股份有限公司 一种达比加群酯药物组合物及其制备方法
EP3771465A1 (en) 2019-08-01 2021-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising dabigatran etexilate
CN111150714A (zh) * 2020-03-17 2020-05-15 南京嘉晨医药科技有限公司 一种甲磺酸达比加群酯固体药物制剂及其制备方法
EP4465969A1 (en) 2022-01-21 2024-11-27 Adamed Pharma S.A. A process for preparation of tartaric acid cores for dabigatran pellets and the pellets containing dabigatran
GR1010399B (el) * 2022-04-05 2023-02-03 Φαρματεν Α.Β.Ε.Ε., Φαρμακευτικο σκευασμα που περιλαμβανει εναν αντιπηκτικο παραγοντα και μεθοδος παραγωγης αυτου
WO2024217830A1 (en) 2023-03-30 2024-10-24 Adamed Pharma S.A A process for preparation of hard capsules filled with dabigatran pellets

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) * 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
US4145308A (en) * 1977-07-07 1979-03-20 General Electric Company Anti-foam silicone emulsion, and preparation and use thereof
US4191741A (en) * 1978-09-22 1980-03-04 Eli Lilly And Company Removable drug implant
US5422121A (en) * 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
US6414008B1 (en) * 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
GB0003782D0 (en) * 2000-02-17 2000-04-05 Dumex Ltd As Process
CA2476054C (en) * 2002-03-07 2011-11-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical composition for the oral administration of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino)-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino)-propionic acid ethyl ester and the salts thereof
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
AR042407A1 (es) 2002-03-13 2005-06-22 Pablo Fuchsberger Envase para medicamentos en capsula, pastillas o similar, y su procedimiento de fabricacion
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
DE10339862A1 (de) 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
US20050107438A1 (en) * 2003-09-03 2005-05-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising 3-[(2-{[4-(Hexyloxycarbonylaminoiminomethyl) phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester or a salt therefore
EP1609784A1 (de) * 2004-06-25 2005-12-28 Boehringer Ingelheim Pharma GmbH & Co.KG Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen
DE102005020002A1 (de) * 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
DE102005025728A1 (de) * 2005-06-04 2006-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
DE102005061623A1 (de) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen
DE102005061624A1 (de) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von Salzen von 4-(Benzimidazolylmethylamino)-Benzamidinen
AR062057A1 (es) 2006-07-17 2008-10-15 Boehringer Ingelheim Int Uso de los inhibidores directos de la trombina
EP2043691A1 (en) 2006-07-17 2009-04-08 Boehringer Ingelheim International GmbH New paediatric indications for direct thrombin inhibitors
US20100087488A1 (en) * 2006-10-10 2010-04-08 Boehringer Ingelheim International Gmgh Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
DE102006054005A1 (de) * 2006-11-16 2008-05-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
EP1956018A1 (de) * 2007-02-06 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Herstellung eines Benzimidazolderivats
US20110129538A1 (en) 2008-03-28 2011-06-02 Boehringer Ingelheim International Gmbh Process for preparing orally administered dabigatran formulations
EP2271317B1 (de) 2008-03-28 2017-04-19 Boehringer Ingelheim International GmbH Verfahren zur herstellung von säurepellets
AR072143A1 (es) * 2008-06-16 2010-08-11 Boehringer Ingelheim Int Procedimiento para la preparacion de un producto intermedio para la sintesis de etexilato de dabigatran
JP5642670B2 (ja) * 2008-06-16 2014-12-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ダビガトランの合成の中間体の製造方法
EP2391893B1 (en) * 2009-02-02 2014-09-03 Boehringer Ingelheim International GmbH Lyophilised dabigatran
US8399678B2 (en) * 2009-11-18 2013-03-19 Boehringer Ingelheim International Gmbh Process for the manufacture of dabigatran etexilate

Also Published As

Publication number Publication date
US20130251811A1 (en) 2013-09-26
TWI436994B (zh) 2014-05-11
JP2011527318A (ja) 2011-10-27
AU2009272796A1 (en) 2010-01-21
US20110123635A1 (en) 2011-05-26
RU2529798C2 (ru) 2014-09-27
WO2010007016A1 (en) 2010-01-21
CL2010001588A1 (es) 2011-06-17
MX2011000480A (es) 2011-05-02
KR20110039261A (ko) 2011-04-15
US9089488B2 (en) 2015-07-28
NZ589746A (en) 2012-10-26
CA2730218A1 (en) 2010-01-21
TW201006818A (en) 2010-02-16
EP2638897A1 (en) 2013-09-18
IL209346A0 (en) 2011-01-31
EP2296631A1 (en) 2011-03-23
AR072557A1 (es) 2010-09-08
RU2011105056A (ru) 2012-08-20
CN102099012A (zh) 2011-06-15

Similar Documents

Publication Publication Date Title
BRPI0915942A2 (pt) método para produção de compostos medicinais contendo dabigatrana
PE20151890A1 (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
MX2010010647A (es) Proceso para preparar formulaciones de dabigatran para administracion oral.
BRPI0911476A2 (pt) compostos ativadores de glicoquinase de piridazinona, composição farmaceutica, uso dos compostos, método para tratamento de uma enfermidade e/ou distúbio metabólico e processo para a preparação dos compostos
EA201490569A1 (ru) Полиморфная форма гидрохлорида придопидина
BR112013000248A2 (pt) derivados de dióxido de 1,3-propano espirociclicamente substituído, método para a produção dos mesmos e uso dos mesmos como medicamento
BR112014015363A8 (pt) derivados de ácido alfa-amino borônico, inibidores de imunoproteassoma seletivos
BR112014031375A2 (pt) moduladores da série de reação complementar e usos dos mesmos
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
BR112013000255A2 (pt) ácidos hidróxifenil-hexinoicos substituídos por ariloxialquileno, método para preparação dos mesmos e seu uso dos mesmos como um medicamento
BR112014010576A8 (pt) compostos inibidores de neprilisina (nep), seus usos, processo de preparação dos compostos e composição farmacêutica compreendendo os compostos
BR112012027062A2 (pt) composto, processo para a preparação de um composto, método para prevenção e/ou tratamento de doenças e condições, e, composição farmacêutica
CR20130534A (es) Nuevos derivados de imidazol útiles para el tratamiento de artritis
CU20130082A7 (es) 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
BR112014003079A2 (pt) derivado de 1,2,3,4-tetra-hidroquinolina útil para o tratamento de diabetes
BR112014018959A8 (pt) Compostos, composições farmacêuticas, utilizações de um composto e métodos para o tratamento do câncer
BR112014027359A2 (pt) moduladores da série de reação complementar e usos dos mesmos
UY31351A1 (es) (ciclopropilfenil)feniloxamidas, procedimiento para su preparación y su uso como medicamentos
BR112015000106A2 (pt) moduladores heterocíclicos de síntes de lipídio
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
BR112013000254A2 (pt) derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2
BR112012012903A2 (pt) compostos de espiropiperidina
MX2010008051A (es) Nuevos derivados de fluoroglicosidos aromaticos, productos farmaceuticos que comprenden dichos compuestos y uso de los mismos.
BR112015008717A2 (pt) composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2519 DE 16-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]